Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
NEW YORK, Dec. 09, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Osiris Therapeutics, Inc. (“Osiris Therapeutics”) (NASDAQ:OSIR) between May 12, 2014 through November 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. If you purchased or otherwise acquired Osiris Therapeutics between May 12, 2014 and November 20, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/osiris-therapeutics-osir
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
